RAGE signaling in cell adhesion and inflammation

Current Pediatric Reviews

Volumn 3, Issue 1, 2007, Pages 1-9

  Lange Sperandio, Bärbel ^a   Sperandio, Markus ^a   Nawroth, Peter ^a   Bierhaus, Angelika ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemokines; Chronic kidney disease (CKD); Cytokines; Proinflammatory; RAGE expression

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BETA2 INTEGRIN; CALGRANULIN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; ISOPROTEIN; LIGAND; MAC1 PROTEIN; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN S 100; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR; UNCLASSIFIED DRUG;

AGING; ALLERGIC ENCEPHALITIS; ATHEROSCLEROSIS; BETA SHEET; CELL ADHESION; CHRONIC INFLAMMATION; DEGENERATIVE DISEASE; DELAYED HYPERSENSITIVITY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG TARGETING; FIBER; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LIGAND BINDING; NONHUMAN; ORGANOGENESIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION; TUMOR; UPREGULATION;

EID: 33847314061     PISSN: 15733963     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339607779941598     Document Type: Review

References (127)

1. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83(11): 876-886.
2. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15(7):16R-28R.
3. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289(4): F645-F659.
4. Ramasamy R, Yan SF, Schmidt AM. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond. Trends Cardiovasc Med 2005; 15(7): 237-243.
5. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91(6): 2463-2469.
6. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70(2): 138-151.
7. Vlassara. H, Brownlee M, Cerami A. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J Exp Med 1984; 160(1):197-207.
8. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267(21): 14998-15004.
9. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267(21): 14987-14997.
10. Schmidt AM, Mora R, Cao R, et al. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 1994; 269(13): 9882-9888.
11. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272(28): 17810-17814.
12. Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105(7): 816-822.
13. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002; 59(7): 1117-1128.
14. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993; 91(5): 2155-2168.
15. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2005; 4(3): 249-266.
16. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108(7): 949-955.
17. Sugaya K, Fukagawa T, Matsumoto K, et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994; 23(2): 408-419.
18. Xu D, Kyriakis JM. Phosphatidylinositol 3pm-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products. J Biol Chem 2003; 278(41): 39349-39355.
19. Malherbe P, Richards JG, Gaillard H, et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 1999; 71(2): 159-170.
20. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370(Pt3): 1097-1109.
21. Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms - a result of regulated alternative splicing? Biochim Biophys Acta 2003; 1630(1): 1-6.
22. Hanford LE, Enghild JJ, Valnickova Z, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2004; 279(48): 50019-50024.
23. Park IH, Yeon SI, Youn JH, et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 2004; 40(16): 1203-1211.
24. Hori O, Brett J, Slattery T, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270(43): 25752-25761.
25. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143(6): 1699-1712.
26. Du YS, Zhu H, Fu J, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a pro-inflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A 1997; 94(10): 5296-5301.
27. Chavakis T, Bierhaus A, Al Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198(10):1507-1515.
28. Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113(11):1641-1650.
29. Lange-Sperandio B, Schimpgen K, Rodenbeck B, et al. Distinct roles of Mac-1 and its counter-receptors in neonatal obstructive nephropathy. Kidney Int 2006; 69(1):81-88.
30. Lai KN, Leung JC, Chan LY, et al. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol 2004; 138(3): 466-475.
31. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275(33): 25781-25790.
32. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel pro-inflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97(7): 889-901.
33. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322(4): 1111-1122.
34. Andersson U, Tracey KJ. HMGB1 in sepsis. Scand J Infect Dis 2003; 35(9): 577-584.
35. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003; 254(4): 375-385.
36. Chapman MR, Robinson LS, Pinkner JS, et al. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 2002; 295(5556): 851-855.
37. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382(6593): 685-691.
38. Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000; 6(6): 643-651.
39. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285(5425): 248-251.
40. Sasaki N, Takeuchi M, Chowei H, et al. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett 2002; 326(2): 117-120.
41. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108(7): 949-955.
42. Roth J, Vogl T, Sunderkotter C, Sorg C. Chemotactic activity of S100A8 and S100A9. J Immunol 2003; 171(11):5651.
43. Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem 2003; 278(37): 34834-34844.
44. Begany DP, Carcillo JA, Herzer WA, Mi Z, Jackson EK. Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. J Pharmacol Exp Ther 1996; 278(1): 37-41.
45. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50(12): 2792-2808.
46. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15): 1066-1071.
47. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272(26): 16498-16506.
48. Bierhaus A, Chen J, Liliensiek B, Nawroth PP. LPS and cytokine-activated endothelium. Semin Thromb Hemost 2000; 26(5): 571-587.
49. Schiekofer S, Balletshofer B, Andrassy M, Bierhaus A, Nawroth PP. Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost 2000; 26(5): 503-511.
50. Cataldegirmen G, Zeng S, Feirt N, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005; 201(3): 473-484.
51. Li JH, Wang W, Huang XR, et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 2004; 164(4): 1389-1397.
52. Gu L, Hagiwara S, Fan Q, et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006. Feb: 21(2): 299-313. Epub 2005 Nov 1.
53. Loeser RF, Yammani RR, Carlson CS, et al. Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis. Arthritis Rheum 2005; 52(8): 2376-2385.
54. Sorci G, Riuzzi F, Agneletti AL, Marchetti C, Donato R. S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner. J Cell Physiol 2004; 199(2): 274-283.
55. Cortizo AM, Lettieri MG, Barrio DA, Mercer N, Etcheverry SB, McCarthy AD. Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 2003; 250(1-2): 1-10.
56. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 2003; 550(1-3): 107-113.
57. Yeh CH, Sturgis L, Haidacher J, et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001; 50(6): 1495-1504.
58. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405(6784): 354-360.
59. Ge J, Jia Q, Liang C, et al. Advanced glycogylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol 2005; 25(10): 2157-2163.
60. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274(28): 19919-19924.
61. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001; 81(1): 102-113.
62. Hasegawa T, Kosaki A, Kimura T, et al. The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. Atherosclerosis 2003; 171(2): 211-218.
63. Brizzi MF, Dentelli P, Rosso A, et al. FASEB J 2004; 18(11): 1249-1251.
64. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280(5): E685-E694.
65. Mukherjee TK, Mukhopadhyay S, Hoidal JR. The role of reactive oxygen species in TNFalpha-dependent expression of the receptor for advanced glycation end products in human umbilical vein endothelial cells. Biochim Biophys Acta 2005; 1744(2): 213-223.
66. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004; 6(13): 1219-1225.
67. Butcher EC. Leukocyte-endothelial cell recognition - Three (or more) steps to specificity and diversity. Cell 1991; 67: 1033-1036.
68. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995; 57: 827-872.
69. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999; 79(1): 181-213.
70. Dunne JL, Collins RG, Beaudet AL, Ballantyne CM, Ley K. Mac - 1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-alpha-induced inflammation. J Immunol 2003; 171(11): 6105-6111.
71. Wendt T, Harja E, Bucciarelli L, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2005 Mar: 185(1):70-7. Epub 2005 Aug 1.
72. Lalla E, Lamster IB, Stern DM, Schmidt AM. Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities. Ann Periodontol 2001; 6(1): 113-118.
73. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162(4): 1123-1137.
74. Bierhaus A, Haslbeck KM, Humpert PM, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004; 114(12): 1741-1751.
75. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4(9): 1025-1031.
76. Drinda S, Franke S, Ruster M, et al. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int 2005; 25(6): 411-413.
77. Chen Y, Yan SS, Colgan J, et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol 2004; 173(2): 1399-1405.
78. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159(2):513-525.
79. Hudson BI, Schmidt AM. RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm Res 2004; 21(7): 1079-1086.
80. Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001; 171(1): 29-45.
81. Arancio O, Zhang HP, Chen X, et,al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004; 23 (20): 4096-4105.
82. Constien R, Forde A, Liliensiek B, et al. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 2001; 30(1): 36-44.
83. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162(4): 1123-1137.
84. Bierhaus A, Haslbeck KM, Humpert PM, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004; 114(12): 1741-1751.
85. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111(7): 959-972.
86. Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001; 21(6): 905-910.
87. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93(12): 1159-1169.
88. Jandeleit-Dahm K, Lassila M, Davis BJ, et al. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. J Hypertens 2005; 23(11): 2071-2082.
89. Jandeleit-Dahm KA, Lassila M, Allen TJ. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies. Ann N Y Acad Sci 2005; 1043: 759-766.
90. Mackic JB, Stins M, McComb JG, et al. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothetial cell monolayer. J Clin Invest 1998; 102(4):734-743.
91. Hudson BI, Bucciarelli LG, Wendt T, et al. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 2003; 419(1): 80-88.
92. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108(2):261-268.
93. Schwenger V, Morath C, Salava A, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17(1):199-207.
94. Yan SS, Wu ZY, Zhang HP, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003; 9(3): 287-293.
95. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54(6):1615-1625.
96. Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifyirig arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003; 108(9): 1070-1077.
97. Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11(9): 1656-1666.
98. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325(12):836-842.
99. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 2005; 1043: 452-460.
100. Miyata T, Horie K, Ueda Y, et al. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58(1):425-435.
101. Miyata T, Sugiyama S, Suzuki D, Inagi R, Kurokawa K. Increased carbonyl modification by lipids and carbohydrates in diabetic nephropathy. Kidney Int Suppl 1999; 71:S54-S56.
102. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999; 10(4):822-832.
103. Hou FF, Ren H, Owen WF, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004; 15(7): 1889-1896.
104. Hudson BI, Stickland MH, Grant PJ, Futers TS. Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5′ regulatory region on chromosome 3: implications for polymorphic studies in diabetes. Diabetes 2001; 50(12): 2646-2651.
105. Hudson BI, Stickland MH, Futers TS, Grant PJ. Study of the -429 T/C and -374 T/A receptor for advanced glycation end products promoter polymorphisms in diabetic and nondiabetic subjects with macrovascular disease. Diabetes Care 2001; 24(11):2004.
106. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001; 50(6): 1505-1511.
107. Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 1998; 47(7):1155-1157.
108. Rudofsky G Jr, Isermann B, Schilling T, et al. A 63bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112(3): 135-141.
109. Sullivan CM, Futers TS, Barrett JH, Hudson BI, Freeman MS, Grant PJ. RAGE polymorphisms and the heritability of insulin resistance: the Leeds family study. Diab Vasc Dis Res 2005; 2(1): 42-44.
110. Steenvoorden MM, Huizinga TW, Verzijl N, et al. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 2006; 54(1): 253-263.
111. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005; 7(4):R817-R824.
112. Moser B, Hudson BI, Schmidt AM. Soluble RAGE: a hot new biomarker for the hot joint? Arthritis Res Ther 2005; 7(4): 142-144.
113. Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol 2005; 175(12): 8296-8302.
114. Andrassy M, Igwe J, Autschbach F, et al. Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am J Pathol 2006; 169(4): 1223-1237.
115. Ma L, Nicholson LF. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res 2004; 1018(1): 10-17.
116. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 2005; 64(9): 816-830.
117. Emanuele E, D'Angelo A, Tomaino C, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005; 62(11): 1734-1736.
118. Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23(9):1725-1729.
119. Hwang JS, Shin CH, Yang SW. Clinical implications of N epsilon-(carboxymethyl) lysine, advanced glycation end product, in children and adolescents with type 1 diabetes. Diabetes Obes Metab 2005; 7(3): 263-267.
120. Galler A, Muller G, Schinzel R, Kratzsch J, Kiess W, Munch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care 2003; 26(9): 2609-2615.
121. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF. The advanced glycation end product Nepsilon-(carboxymethyl) lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 1998; 21(11): 1997-2002.
122. Nicoloff G, Baydanoff S, Petrova C, Christova P. Antibodies to advanced glycation end products in children with diabetes mellitus. Vascul Pharmacol 2002; 39(1-2):39-45.
123. Misselwitz J, Franke S, Kauf E, John U, Stein G. Advanced glycation end products in children with chronic renal failure and type 1 diabetes. Pediatr Nephrol 2002; 17(5): 316-321.
124. Sebekova K, Podracka L, Blazicek P, Syrova D, Heidland A, Schinzel R. Plasma levels of advanced glycation end products in children with renal disease. Pediatr Nephrol 2001; 16(12): 1105-1112.
125. Sebekova K, Podracka L, Heidland A, Schinzel R. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation-are they inter-related? Clin Nephrol 2001; 56(6): S21-S26.
126. Bayazit AK, Vogt BA, Dell KM, et al. Effect of the peritoneal dialysis prescription on pentosidine in children. Pediatr Nephrol 2003; 18(10): 1049-1054.
127. Varvarovska J, Racek J, Stetina R, et al. Aspects of oxidative stress in children with type 1 diabetes mellitus. Biomed Pharmacother 2004; 58(10): 539-545.